Genetic toxicology of remifentanil, an opiate analgesic

Teratogenesis Carcinogenesis and Mutagenesis

Volumn , Issue SUPPL. 1, 2003, Pages 137-149

  Allen, Jane S ^a   Campbell, James A ^a   Cariello, Neal F ^a   Kutz, Stephen A ^a   Thilagar, Arul ^b   Xu, Jing ^b   Ham, Andrea L ^c,e   Mitchell, Ann D ^d  

^a GLAXOSMITHKLINE   (United States)

^b SITEK Research Laboratories   (United States)

^c UK   (United States)

^d Genesys Research   (United States)

^e Du Pont Pharmaceutical Co   (United States)

Author keywords

Ames test; Chromosome aberration; Genetic toxicology; GI87084; Micronucleus; Mouse lymphoma assay; Opioid; Remifentanil; Unscheduled DNA synthesis

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; FENTANYL; HYCANTHONE; OPIATE AGONIST; REMIFENTANIL; TRETAMINE;

AMES TEST; ANIMAL CELL; BIOASSAY; CHROMOSOME ABERRATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ACTIVATION; GENETIC TOXICOLOGY; GENOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLIC ACTIVATION; MICRONUCLEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

CRICETINAE; CRICETULUS GRISEUS;

EID: 0037288345     PISSN: 02703211     EISSN: None     Source Type: Journal    
DOI: 10.1002/tcm.10069     Document Type: Conference Paper

References (27)

1. Burkle H, Dunbar S, Van Aken H. Remifentanil: a novel, shot-acting mu-opioid. Anesth Analg 1996;8:646-651.
2. Physicians' Desk Reference (hereafter PDR) 54th ed. Oradell, NJ: Medical Economics; 2000. p 1286-1290.
3. Feldman PL, James MK, Brackeen MF, Bilotta JM, Schuster SV, Lahey AP, Lutz MW, Johnson MR, Leighton HJ. Design, synthesis, and pharmacological evaluation of ultrashort to long-acting opioid analgesics. J Med Chem 1991;34:2202-220.
4. Chism JP, Rickert DE. The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. Drug Metab Dispos 1996;24:34-40.
5. Olufolabi AJ, Booth JV, Wakeling HG, Glass PS, Penning DH, Reynolds JD. A preliminary investigation of remifentanil as a labor analgesic. Anesth Analg 2000;91:606-608.
6. Litman RS. Conscious sedation with remifentanil during painful medical procedures. J Pain Sympt Manage 2000;19:468-471.
7. Zarate E, Latham P, White PF, Bossard R, Morse L, Douning LK, Shi C, Chi L. Fast-track cardiac anesthesia: use of remifentanil combined with intrathecal morphine as an alternative to sufentanil during desflurane anesthesia. Anesth Analg 2000;91:283-287.
8. Bekker AY, Berklayd P, Osborn I, Bloom M, Yarmush J, Turndorf H. The recovery of cognitive function after remifentanil-nitrous oxide anesthesia is faster than after an isoflurane-nitrous oxide- fentanyl combination in elderly patients. Anesth Analg 2000;91:117-122.
9. Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 1975;31:347-364.
10. Maron D, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res 1983;113:173-215.
11. Galloway SM, Aardema MJ, Ishidate M Jr, Ivett JL, Kirkland DJ, Morita T, Mosesso P, Sofuni T. Report from working group on in vitro tests for chromosomal aberrations. Mutat Res 1994;312:241-261.
12. Margolin BH, Resnick MA, Rimpo JY, Archer P, Galloway SM, Bloom AD, Zeiger E. Statistical analysis for in vitro cytogenetics assays using Chinese hamster ovary cells. Environ Mutagen 1986;8:183-204.
13. Mitchell AD, Myhr BC, Rudd CJ, Caspary WJ, Dunkel VC. Evaluation of the L5178Y mouse lymphoma cell mutagenesis assay: methods used and chemicals evaluated. Environ Mol Mutagen 1988;12(Suppl 13):37-101.
14. Mitchell AD. Alternate hypothesis for the bimodal size distribution of mutant colonies of L5178Y mouse lymphoma cells. Environ Mol Mutagen 1997;29:431-433.
15. Clive D, Glover P, Applegate M, Hozier J: Molecular aspects of chemical mutagenesis in L5178Y/tk +/- mouse lymphoma cells. Mutagenesis 1990;5:191-197.
16. +/-, mouse lymphoma cells. Mutat Res 1985;151:147-159.
17. Gudi R, Xu J, Thilager A. Assessment of the in vivo aneuploidy/micronucleus assay in mouse bone marrow cells with 16 chemicals. Environ Mol Mutagen 1992;20:106-116.
18. Butterworth BE, Ashby J, Bermudez E, Casciano D, Mirsalis J, Probst G, Williams G. A protocol and guide for the in vivo rat hepatocyte DNA-repair assay. Mutat Res 1987;189:123-133.
19. Williams GM. Carcinogen-induced DNA repair in primary rat liver cell cultures: a possible screen for chemical carcinogens. Cancer Lett 1977;1:231-237.
20. Williams GM. Detection of chemical carcinogens by unscheduled DNA synthesis in rat livery primary cell cultures. Cancer Res 1977;37:1845-1851.
21. Mirsalis JC, Tyson CK, Butterworth BE. Detection of genotoxic carcinogens in the in vivo-in vitro hepatocyte DNA repair assay. Environ Mutagen 1982;4:553-562.
22. Snyder RD and Green JW. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 2001;488:151-169.
23. PDR, 49th ed. Oradell, NJ. Medical Economics; 1995. p 821, 1180.
24. PDR, 54th ed. Oradell, NJ. Medical Economics; 2000. p 1250, 1288.
25. PDR, 55th ed. Oradell, NJ. Medical Economics; 2001. p 580, 669, 1209, 2785, 2885.
26. Muller L, Kaspar P. Human biological relevance and the use of threshold arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat Res 2000;464:19-34.
27. PDR, 48th ed. Oradell, NJ. Medical Economics, 1994. p 1082, 1085.